Boothbay Fund Management LLC Sells 43,439 Shares of Novo Nordisk A/S (NYSE:NVO)

Boothbay Fund Management LLC decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 65.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,833 shares of the company’s stock after selling 43,439 shares during the period. Boothbay Fund Management LLC’s holdings in Novo Nordisk A/S were worth $1,964,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of NVO. Center for Financial Planning Inc. increased its holdings in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after buying an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL grew its stake in shares of Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares during the period. Transce3nd LLC purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $33,000. Kelly Lawrence W & Associates Inc. CA purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $39,000. Finally, Albion Financial Group UT lifted its position in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.9 %

Novo Nordisk A/S stock opened at $62.07 on Monday. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $148.15. The firm has a market capitalization of $278.54 billion, a price-to-earnings ratio of 18.87, a P/E/G ratio of 0.90 and a beta of 0.61. The firm has a 50 day moving average of $73.62 and a 200 day moving average of $89.42. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were paid a dividend of $0.7874 per share. This represents a yield of 1.2%. The ex-dividend date was Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.54%.

Analysts Set New Price Targets

NVO has been the subject of a number of research reports. Guggenheim lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Morgan Stanley started coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. BMO Capital Markets reaffirmed a “market perform” rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, BNP Paribas began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an “underperform” rating for the company. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.